Cogent Biosciences (COGT) director takes options in lieu of cash

Rhea-AI Filing Summary

Cogent Biosciences director Karen Jean Ferrante reported receiving a grant of stock options as compensation. On July 1, 2026, she was awarded 627 stock options to buy Cogent Biosciences common stock at an exercise price of $38.48 per share.

The options were issued under the company’s non-employee director compensation plan after she elected to take equity instead of cash fees for the quarter. These options expire on July 1, 2036, and following the grant she holds 627 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ferrante Karen Jean

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	627	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 627 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 627 options Exercise price: $38.48 per share Underlying shares: 627 shares +2 more

5 metrics

Options granted 627 options Stock option grant on July 1, 2026

Exercise price $38.48 per share Stock option exercise price

Underlying shares 627 shares Common stock underlying the options

Expiration date July 1, 2036 Option expiration for this grant

Derivative holdings after grant 627 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), non-employee director compensation plan, Black-Scholes value

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

non-employee director compensation plan financial

"pursuant to the Issuer's non-employee director compensation plan"

Black-Scholes value financial

"by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 04:31 PM Accepted by SEC EDGAR 07/06/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferrante Karen Jean

(Last) (First) (Middle)

C/O COGENT BIOSCIENCES, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.48	07/01/2026		A		627		07/01/2026	07/01/2036	Common Stock	627	$0(1)	627	D

Explanation of Responses:

1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

	/s/ Evan D. Kearns, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Karen Jean Ferrante report in her latest Cogent Biosciences (COGT) Form 4?

Karen Jean Ferrante reported receiving a grant of 627 stock options to buy Cogent Biosciences common stock at $38.48 per share. The options were issued as quarterly director compensation in equity rather than cash and expire on July 1, 2036.

How many Cogent Biosciences (COGT) options did Karen Jean Ferrante receive?

She received 627 stock options as part of her non-employee director compensation. These options give her the right to purchase 627 shares of Cogent Biosciences common stock at a fixed exercise price, aligning her compensation with the company’s long-term performance.

What is the exercise price of Karen Jean Ferrante’s Cogent Biosciences (COGT) stock options?

The exercise price of her stock options is $38.48 per share. This means she can later buy Cogent Biosciences common stock at $38.48 regardless of future market price, subject to the option terms and the July 1, 2036 expiration date.

Why did Karen Jean Ferrante receive Cogent Biosciences (COGT) options instead of cash?

She elected to take stock options in lieu of cash fees under Cogent Biosciences’ non-employee director compensation plan. The number of options was calculated by dividing the cash compensation for the quarter by the Black-Scholes value of a single option at grant.

When do Karen Jean Ferrante’s Cogent Biosciences (COGT) stock options expire?

Her stock options expire on July 1, 2036, giving a long-term window to exercise the right to buy shares. After that date, any unexercised options become worthless and can no longer be converted into Cogent Biosciences common stock.